Your browser doesn't support javascript.
Finding potent inhibitors for COVID-19 main protease (Mpro): an in silico approach using SARS-CoV-3CL protease inhibitors for combating CORONA.
Motiwale, Mohit; Yadav, Neetu Singh; Kumar, Sushil; Kushwaha, Tushar; Choudhir, Gourav; Sharma, Supriya; Singour, Pradeep Kumar.
  • Motiwale M; Computational and Synthetic Chemistry Lab, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, VNS Group of Institutions, Bhopal, India.
  • Yadav NS; Department of Biochemical Engineering and Biotechnology, Indian Institute of Technology, Delhi, New Delhi, India.
  • Kumar S; Department of Botany, Shaheed Mangal Pandey Govt. P.G. College, Madhavpurum, Meerut, India.
  • Kushwaha T; Department of Biophysics, All India Institute of Medical Sciences, New Delhi, India.
  • Choudhir G; Department of Botany, CCS University, Meerut, Meerut, India.
  • Sharma S; Computational and Synthetic Chemistry Lab, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, VNS Group of Institutions, Bhopal, India.
  • Singour PK; Computational and Synthetic Chemistry Lab, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, VNS Group of Institutions, Bhopal, India.
J Biomol Struct Dyn ; 40(4): 1534-1545, 2022 03.
Article in English | MEDLINE | ID: covidwho-2273004
ABSTRACT
SARS-CoV-2 is liable for the worldwide coronavirus disease (COVID-19) exigency. This pandemic created the need for all viable treatment strategies available in the market. In this scenario, computer-aided drug design techniques can be efficiently applied for the quick identification of promising drug repurposing candidates. In the current study, we applied the molecular docking approach in conjugation with molecular dynamics (MD) simulations to find out potential inhibitors against Mpro of SARS-CoV-2 from previously reported SARS-3CL protease inhibitors. Our results showed that N-substituted isatin derivatives and pyrazolone compounds could be used as a potent inhibitor and may possess an anti-viral activity against SARS-CoV-2. However, further experimental investigation and validation of the selected hits are required to find out their suitability for clinical trials. Communicated by Ramaswamy H. Sarma.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Protease Inhibitors / COVID-19 Type of study: Prognostic study Limits: Humans Language: English Journal: J Biomol Struct Dyn Year: 2022 Document Type: Article Affiliation country: 07391102.2020.1829501

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Protease Inhibitors / COVID-19 Type of study: Prognostic study Limits: Humans Language: English Journal: J Biomol Struct Dyn Year: 2022 Document Type: Article Affiliation country: 07391102.2020.1829501